Hinova's Heterocyclic AR Degrader EP4378936A1

The European Patent Office granted Hinova Pharmaceuticals Inc. a patent covering bifunctional chimeric heterocyclic compounds as androgen receptor degraders. The patent application EP4378936A1 was published with international patent classifications C07D 401/04, C07D 401/14, A61K 31/496, A61K 31/4439, and A61P 35/00, indicating pharmaceutical applications for cancer treatment.

For pharmaceutical companies and biotech firms, this patent represents a protected chemical scaffold for developing androgen receptor-targeting cancer therapies. Companies engaged in prostate cancer drug development should consider potential freedom-to-operate implications. The patent's designation across 31 EPO member states provides broad geographic coverage within Europe for intellectual property protection of related compound families.